| Identification | Back Directory | [Name]
D-Serine, N-[[2-(2,1,3-benzoxadiazol-5-ylmethoxy)-4-[(2-bromo[1,1'-biphenyl]-3-yl)methoxy]-5-chlorophenyl]methyl]-, ethyl ester, hydrochloride (1:1) | [CAS]
2597056-04-5 | [Synonyms]
D-Serine, N-[[2-(2,1,3-benzoxadiazol-5-ylmethoxy)-4-[(2-bromo[1,1'-biphenyl]-3-yl)methoxy]-5-chlorophenyl]methyl]-, ethyl ester, hydrochloride (1:1) | [Molecular Formula]
C32H30BrCl2N3O6 | [MOL File]
2597056-04-5.mol | [Molecular Weight]
703.41 |
| Hazard Information | Back Directory | [Uses]
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1]. | [Biological Activity]
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1]. | [storage]
Store at -20°C | [References]
[1]. Liu L, et al. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. J Med Chem. 2021;64(12):8391-8409. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|